Alben-VC Special Precautions

Bone marrow suppression, aplastic anemia, and agranulocytosis may occur, including fatalities; monitoring recommended.
Cerebral hyperetensive episodes may occur during the first week of neurocysticercosis therapy; pretreatment recommended.
Elevations of hepatic enzymes may occur; increase risk of hepatotoxicity and bone marrow suppression; monitoring recommended; discontinuation of therapy may be warranted.
Hepatic disease, preexisting; increase risk of bone marrow suppression leading to pancytopenia, aplastic anemia, agranulocytosis, and leukopenia; monitoring recommended; discontinuation of therapy may be warranted.
Preexisting neurocysticercosis, previously undiagnosed; may experience neurological symptoms (eg. Seizures, increased intracranial pressure, and focal signs) which may occur soon after treatment and require medical management.
Retinal lesions; increase risk of retinal damage in patients with cysticercosis; weigh the risks versus benefits of therapy.